Theravance Biopharma, Inc.
Ticker: 1583107
values in millions
Revenue & Profit Trend
in millionsRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|
| INCOME | ||||||||
| Revenue | 20.73+17.1% | 17.70-11.5% | 19.99-23.7% | 26.20+70.2% | 15.39-8.8% | 16.87+18.3% | 14.26-1.7% | 14.50 |
| Total Income | 20.73+17.1% | 17.70-11.5% | 19.99-23.7% | 26.20+70.2% | 15.39-8.8% | 16.87+18.3% | 14.26-1.7% | 14.50 |
| EXPENSES | ||||||||
| Expenditure | 29.01+6.7% | 27.18+2.8% | 26.45-8.5% | 28.92-3.0% | 29.82+7.6% | 27.71-7.5% | 29.96+16.5% | 25.71 |
| Tax | 1.11+172.1% | -1.54+76.3% | -6.50-135.4% | 18.37+3380.4% | -0.56-121.1% | 2.65+102.3% | 1.31+4.0% | 1.26 |
| PROFIT | ||||||||
| PBT | -4.79+26.0% | -6.47-123.9% | -2.89-103.9% | 73.21+617.8% | -14.14-40.7% | -10.05+34.0% | -15.22-46.3% | -10.40 |
| Net Profit | -5.90-19.7% | -4.93-236.2% | 3.62-93.4% | 54.84+503.8% | -13.58-6.9% | -12.70+23.2% | -16.53-41.8% | -11.66 |
| KEY METRICS | ||||||||
| OPM % | -39.93%+13.65pp | -53.58%-21.29pp | -32.29%-21.89pp | -10.40%+83.40pp | -93.80%-29.55pp | -64.25%+35.75pp | -100.00%-22.72pp | -77.27% |
| NPM % | -28.45%-0.58pp | -27.87%-45.96pp | 18.08%-81.91pp | 100.00%+188.24pp | -88.24%-12.97pp | -75.28%+24.72pp | -100.00%-19.57pp | -80.42% |
| EPS | -0.11-10.0% | -0.10-242.9% | 0.07-93.6% | 1.09+503.7% | -0.27-3.8% | -0.26+23.5% | -0.34-41.7% | -0.24 |
Corporate Events
Board MeetingTBPH
202618Sep
Board Meeting
Shareholder approval of a merger agreement with Zymeworks In…
SEC Filing ↗ Board MeetingTBPH
202619Jun
Board Meeting
Employment termination of Áine Miller, Senior Vice President…
SEC Filing ↗ Board MeetingTBPH
202612Jun
Board Meeting
Annual General Meeting of Shareholders to elect directors, r…
SEC Filing ↗